繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Qiagen Expands Master Collaboration Agreement with AstraZeneca

2024-08-29 05:31

05:31 PM EDT, 08/28/2024 (MT Newswires) -- Qiagen (QGEN) said late Wednesday it is expanding its master collaboration agreement with AstraZeneca (AZN).

Qiagen will use its QIAstat-Dx syndromic testing platform to develop and validate a genotyping assay that will allow specialty care providers to potentially perform genotyping while patients are undergoing routine clinical examination, the company said.

Price: 45.81, Change: +0.02, Percent Change: +0.04

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。